BioSpace News Archive

A P otential T reatment for Pancreatic Cancer in A ddition to O ther T umors of H igh U nmet C linical N eed CARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has initiated Investigational New Drug, or IND-enabling

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Swissmedic has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older in Switzerland.

Okami Medical Inc., today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the LOBO-7 and LOBO-9 Vascular Occluders, the latest addition to the company’s LOBO® Vascular Occlusion System.

ScImage Inc., a leading provider of Enterprise Imaging solutions and DiA Imaging Analysis, a global leading provider of AI-based cardiac ultrasound software, announced today a commercial partnership to combine ScImage’s unique Cloud architecture with DiA’s AI-based automated cardiac ultrasound solution, LVivo Seamless™.

Find Therapeutics Inc. (Montreal, Quebec) and SATT Conectus (Strasbourg, France) have signed an exclusive worldwide license to develop a promising therapy for Multiple Sclerosis (MS) and Optic Neuritis (ON) based on a new class of compounds.

Prolacta Bioscience®, the world’s leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, announced today that top-ranked analyst David Steinberg has been appointed as chief financial officer.

FORUS Therapeutics Inc (“FORUS”), is pleased to announce that on May 31, 2022 XPOVIO® (selinexor) was authorized for sale by Health Canada in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases announces that Dr. Hubert Chen, MD has joined the company as Chief Scientific Officer and President.

Forte Biosciences, Inc., a biopharmaceutical company focused on autoimmune diseases announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced the publication in Allergy and Rhinology of positive two-year results from a trial evaluating the safety and efficacy of RhinAer® in patients with chronic rhinitis.